Similar Items: Development and Characterization of recombinant immunotoxins for cervical carcinoma
- Development of recombinant immunotoxins targeting overexpressed cell surface biomarkers trophoblast cell-surface antigen 2 and mesothelin for cervical cancer treatment
- Characterization of ADAM10 in cervical and oesophageal cancers
- Development Of Recombinant Immunotherapeutics for Triple-Negative Breast Cancer (TNBC)
- Simulating recombinant sequence date to evaluate and improve computational methods of multiple sequence alignment and recombinant identification
- Late radiation proctitis : the incidence and contributing factors in patients with locally advanced cervical carcinoma treated at Pretoria Academic Hospital
- Molecular characterization of the A52 murine hepatocellular carcinoma cell line
Author: Barth, Stefan
- Evaluation of tumour-associated antigens to optically label cutaneous basal cell carcinoma for surgical excision
- Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
- Generation of Glioblastoma specific SNAP based antibody fusion proteins for future radiolabelling application
- Development and Characterization of recombinant immunotoxins for cervical carcinoma
- Development of potential immunodiagnostic & therapeutic techniques using SNAP-fusion proteins as tools for the validation of Triple-negative Breast Cancer
- Comparison of the therapeutic efficacy of SNAP-tag fusion protein and the synergistic actions of chemotherapy and photodynamic therapy in killing resistant melanoma